证券代码：301060 证券简称：兰卫医学 公告编号：2025-036 上海兰卫医学检验所股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届董事会第六次会议 于 2025 年 9 月 29 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的通知 已于 2025 年 9 月 24 日以邮件形式通知全体董事。会议由公司董事长曾伟雄先生主持， 本次会议应出席董事 7 人，实际出席董事 7 人。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》《上海兰卫医学检验所股份有限公司章程》规定，会议合法、 有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于聘任公司副总经理的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《关于聘任公 司副总经理的公告》（公告编号：2025-037）。 表决结果：同意 7 票，反对 0 票，弃权 0 ...

Core Viewpoint - Lanwei Medical (301060.SZ) reported a significant decline in revenue and net profit for the first half of 2025, indicating ongoing financial challenges despite a positive cash flow from operating activities [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 was 759.39 million yuan, a decrease of 14.50% compared to the same period last year [2]. - The net profit attributable to shareholders was -5.78 million yuan, reflecting a year-on-year decrease of 137.08% [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -7.64 million yuan, down 170.04% year-on-year [2]. - The net cash flow from operating activities was 37.23 million yuan, a significant improvement from -48.14 million yuan in the previous year, marking a 177.35% increase [2]. Future Projections - For 2023 and 2024, the projected operating revenues are 1.67 billion yuan and 1.74 billion yuan, respectively, with net profits expected to remain negative at -142 million yuan and -109 million yuan [3]. - The net profit after deducting non-recurring gains and losses for 2023 and 2024 is projected to be -152 million yuan and -109 million yuan, respectively [3]. Initial Public Offering (IPO) Details - Lanwei Medical raised a total of 200 million yuan from its IPO, with a net amount of 139 million yuan after deducting issuance costs, which was 67.4 million yuan less than originally planned [4]. - The funds raised are intended for laboratory upgrades, information platform construction, and medical testing R&D center projects [4].

Core Viewpoint - Lanwei Medical (301060) announced the election of Ms. Xiong Chang as the employee representative director of the fourth board of directors during the fifth ninth employee representative assembly held on September 19, 2025 [1] Summary by Category - **Company Announcement** - Lanwei Medical held its fifth ninth employee representative assembly on September 19, 2025 [1] - Ms. Xiong Chang was democratically elected as the employee representative director of the fourth board of directors [1]

Group 1 - The company Lanwei Medical (SZ 301060) held its fourth fifth board meeting on September 19, 2025, to discuss the election of Ms. Xiong Chang as a member of the strategic committee [1] - For the first half of 2025, the revenue composition of Lanwei Medical was 51.41% from commercial activities and 48.59% from services [1] - As of the report date, Lanwei Medical has a market capitalization of 3.8 billion yuan [1]

一、董事会会议召开情况 证券代码：301060 证券简称：兰卫医学 公告编号：2025-034 上海兰卫医学检验所股份有限公司 第四届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 本议案无需提交公司股东大会审议。 三、备查文件 1、第四届董事会第五次会议决议。 上海兰卫医学检验所股份有限公司（以下简称"公司"）第四届董事会第五次会议 于 2025 年 9 月 19 日在公司会议室以现场结合通讯会议方式召开。因事项紧急，召开本 次会议的通知于 2025 年 9 月 19 日现场通知全体董事，全体董事会成员同意豁免本次会 议提前通知期限要求。会议由公司董事长曾伟雄先生主持，本次会议应出席董事 6 人， 实际出席董事 6 人。本次会议的召集、召开和表决程序符合《中华人民共和国公司法》 《上海兰卫医学检验所股份有限公司章程》规定，会议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1、审议通过《关于补选熊畅女士为公司第四届董事会战略委员会委员的议案》 具体内容详见公司同日披露于巨潮 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-035 上海兰卫医学检验所股份有限公司 关于公司选举职工代表董事暨补选董事会战略委员会委员的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）于 2025 年 9 月 19 日召开 了 2025 年第一次临时股东大会，审议通过了《关于修订<公司章程>及配套议事规则并 办理工商变更登记的议案》。根据修订后的《上海兰卫医学检验所股份有限公司章程》 （以下简称"《公司章程》"），公司董事会设职工代表董事一名，职工代表董事由公司职 工通过职工代表大会民主选举产生。现将有关事项公告如下： 一、关于选举公司职工代表董事的情况 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《公司章程》等有关规定， 公司于 2025 年 9 月 19 日召开了第五届第九次职工代表大会，经公司职工代表大会民主 选举，由熊畅女士（简历详见附件）担任公司第四届董事会职工代表董事。熊畅女士将 与公司现任第四届董事会非职工代表董事共同组成公司第四届董事会，任期自职工代表 大会 ...

上海澄明则正律师事务所 法律意见书 上海澄明则正律师事务所 关于上海兰卫医学检验所股份有限公司 2025 年第一次临时股东大会的法律意见书 致：上海兰卫医学检验所股份有限公司 上海澄明则正律师事务所（以下简称"本所"），接受上海兰卫医学检验所 股份有限公司（以下简称"公司"）的委托，指派本所律师出席公司 2025 年第 一次临时股东大会（以下简称"本次股东大会"），并根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）以及《上海兰 卫医学检验所股份有限公司章程》（以下简称"《公司章程》"）等规定出具《上 海澄明则正律师事务所关于上海兰卫医学检验所股份有限公司 2025 年第一次临 时股东大会的法律意见书》（以下简称"本法律意见书"）。 本所依据本法律意见书出具日之前已经发生或存在的事实及中国现行法律、 法规及规范性文件发表法律意见。 本所同意将本法律意见书作为公司本次股东大会公告的法定文件，随公司 其他公告一并提交深圳证券交易所审查并予公告。 本所律师已经对公司提供的与本次股东大会有关的文件、资料及 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2025-033 上海兰卫医学检验所股份有限公司 1、本次股东大会未出现否决议案的情形； 2、本次股东大会不涉及变更前次股东大会已通过的决议的情形。 上海兰卫医学检验所股份有限公司（以下简称"公司"）2025 年第一次临时股东大 会于 2025 年 9 月 19 日在公司会议室召开，会议通知已于 2025 年 8 月 26 日以公告形式 发出，本次会议以现场投票与网络投票相结合的方式召开。会议由公司董事长曾伟雄先 生主持。 一、会议召开和出席情况 1、会议召开时间： 现场会议召开时间：2025 年 9 月 19 日（星期五）下午 14:30。 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 网络投票时间：2025 年 9 月 19 日（星期五）。其中 通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投票的具体时间为： 2025 年 9 月 19 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深交所互联网投票系统投票 ...

Group 1 - The core viewpoint of the news is that Lanwei Medical has experienced a decline in stock performance and financial metrics, indicating potential challenges in its business operations [1][2]. - On September 15, Lanwei Medical's stock fell by 1.21%, with a trading volume of 35.50 million yuan. The net financing buy was -1.07 million yuan, indicating more repayments than new purchases [1]. - As of September 15, the total margin balance for Lanwei Medical was 95.06 million yuan, with a financing balance of 95.03 million yuan, accounting for 2.42% of the circulating market value, which is above the 70th percentile of the past year [1]. Group 2 - As of June 30, the number of shareholders for Lanwei Medical was 23,200, a decrease of 3.94% from the previous period, while the average circulating shares per person increased by 5.51% to 15,527 shares [2]. - For the first half of 2025, Lanwei Medical reported operating revenue of 759 million yuan, a year-on-year decrease of 14.50%, and a net profit attributable to the parent company of -5.78 million yuan, a decline of 137.08% [2]. - Since its A-share listing, Lanwei Medical has distributed a total of 320 million yuan in dividends, with 200 million yuan distributed over the past three years [3].

Core Viewpoint - Lanwei Medical (301060) reported disappointing financial results for the first half of 2025, with significant declines in revenue and net profit compared to the previous year [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 759 million yuan, a decrease of 14.5% year-on-year [1]. - The net profit attributable to shareholders was -5.78 million yuan, representing a decline of 137.08% compared to the previous year [1]. - In Q2 2025, total revenue was 409 million yuan, down 9.58% year-on-year, while net profit attributable to shareholders was 2.30 million yuan, a decrease of 84.18% [1]. - The gross profit margin was 22.55%, down 0.93% year-on-year, and the net profit margin was -0.50%, a decline of 144.14% [1]. - Total operating expenses (selling, administrative, and financial expenses) amounted to 122 million yuan, accounting for 16.11% of revenue, an increase of 4.06% year-on-year [1]. - Earnings per share were -0.01 yuan, a decrease of 125.0% year-on-year [1]. Accounts Receivable and Cash Flow - Accounts receivable represented 46.88% of total revenue, indicating a significant amount of outstanding payments [1]. - Operating cash flow per share was 0.09 yuan, an increase of 177.35% year-on-year, reflecting improved cash generation from operations [1]. Significant Changes in Financial Items - Construction in progress increased by 296.07% due to ongoing office renovations [3]. - Short-term borrowings decreased by 36.89% as the company repaid bank loans [3]. - Lease liabilities decreased by 39.58% due to payments made under lease contracts [3]. - Other receivables decreased by 46.27% as the company received payments for equity transfers [3]. - Deferred tax assets decreased significantly, leading to a 586.76% increase in income tax expenses [6]. Investment Returns and Business Evaluation - The company's historical median Return on Invested Capital (ROIC) is 12.25%, but the worst year recorded a ROIC of -6.58%, indicating a weak business model [8]. - The company has reported losses in two out of three annual reports since its listing, suggesting vulnerability in its business operations [8].